From: kristoff@GENBANK.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 31, pt. 1, 28 August 1992
Date: 3 Sep 92 01:56:00 GMT
Distribution: bionet


NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution.  The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------

$$XID NIHGUIDE 19920828 V21N31 P1O1 ************************************
X-comment: RFAs described: NIH-92-HL-09-P, NIH-92-HL-08-P, DA-93-01, DK-93-03

NIH GUIDE - Vol. 21, No. 31 - August 28, 1992

$$INDEX BEGIN *******************************************************

                               NOTICES

$$INDEX N1 **********************************************************

WORKSHOP ON MINIMIZING PAIN AND DISTRESS IN LABORATORY ANIMALS
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH

$$INDEX N2 **********************************************************

NATIONAL HUMAN SUBJECT PROTECTION WORKSHOPS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION

$$INDEX N3 **********************************************************

PHS GRANTS AND CONTRACTS TRAINING COURSE
Public Health Service
INDEX:  PUBLIC HEALTH SERVICE

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$INDEX R1 12/18/92 *************************************************

OBESITY PREVENTION IN AMERICAN INDIANS/ALASKA NATIVES:  COORDINATING
CENTER (RFA NIH-92-HL-09-P)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

$$INDEX R2 12/18/92 *************************************************

OBESITY PREVENTION IN AMERICAN INDIANS/ALASKA NATIVES:  FIELD CENTER
(RFA NIH-92-HL-08-P)
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD

$$INDEX R3 12/11/92 *************************************************

DEVELOPMENT OF INNOVATIVE METHODS TO IDENTIFY MEDICATIONS FOR TREATING
COCAINE ABUSE (RFA DA-93-01)
National Institute on Drug Abuse
INDEX:  DRUG ABUSE

$$INDEX R4 12/03/92 *************************************************

CAREER DEVELOPMENT AWARDS FOR UNDERREPRESENTED MINORITY CLINICIAN-
INVESTIGATORS (RFA DK-93-03)
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES

This publication is also available electronically to institutions via
BITNET or INTERNET.  Alternative access is through the NIH Grant Line
using a personal computer.  Contact Dr. John James at 301/496-7554 for
details, or send an E-mail message to ZNS@NIHCU.

$$INDEX END *********************************************************

                               NOTICES

$$N1 BEGIN **********************************************************

WORKSHOP ON MINIMIZING PAIN AND DISTRESS IN LABORATORY ANIMALS

NIH GUIDE, Volume 21, Number 31, August 28, 1992

P.T. 42; K.W. 0201011, 1014003

National Institutes of Health

The National Institutes of Health (NIH), Office for Protection from
Research Risks (OPRR), is continuing to sponsor workshops on
implementing the Public Health Service Policy on the Humane Care and
Use of Laboratory Animals.  Each of the workshops scheduled for FY 1993
will focus on a specific theme.

The workshops are open to institutional administrators, members of
Institutional Animal Care and Use Committees, laboratory animal
veterinarians, investigators, and other institutional staff who have
responsibility for high-quality management of sound institutional
animal care and use programs.

Date:  December 3-4, 1992

(Topic:  MINIMIZING PAIN AND DISTRESS IN LABORATORY ANIMALS)

Workshop Site:  Nashville, TN

Sponsors:  Vanderbilt University and Meharry Medical College

INQUIRIES

Ms. Marilyn Dasaro
Division of Continuing Medical Education
Vanderbilt University
D-8211 Medical Center North
Nashville, TN  37232-2337
Telephone:  (615) 822-4030
FAX:  (615) 343-0809

$$N1 END ************************************************************

$$N2 BEGIN **********************************************************

NATIONAL HUMAN SUBJECT PROTECTION WORKSHOPS

NIH GUIDE, Volume 21, Number 31, August 28, 1992

P.T. 42; K.W. 0783005

National Institutes of Health
Food and Drug Administration

The Office for Protection from Research Risks (OPRR) of the National
Institutes of Health (NIH) and the Food and Drug Administration (FDA)
are continuing to sponsor a series of workshops on the responsibilities
of researchers, Institutional Review Boards (IRBs), and institutional
officials for the protection of human subjects in research. The
workshops are open to everyone with an interest in research involving
human subjects.  The meetings should be of special interest to those
persons currently serving or about to begin serving as a member of an
IRB.  Issues discussed at these workshops are relevant to all other
Public Health Service agencies.  The current schedule includes the
following:

SOUTHWESTERN WORKSHOP

DATES:  November 16 & 17, 1992

LOCATION:
Wyndham Warwick
5701 Main Street
Houston, TX  77005
Telephone:  (713) 526-1991

SPONSORS:
University of Texas Health Science Center at Houston
Prairie View A & M University

REGISTRATION:
Ms. Paula Knudson
Executive Coordinator
Office of Research Support Committee
University of Texas Health Science Center at Houston
P.O. Box 20036
Houston, TX  77225
Telephone:  (713) 792-5048

TITLE:  Geriatric Research as an Ethical Mandate:  Politics, Policy,
and Problems

DESCRIPTION:  Expanded life expectancies and expanding technologies are
swelling the ranks of the frail and disabled elderly.  Minimal research
has been carried out to understand the problems that this subject group
and their families encounter in finding solutions to their health and
social needs.  The conference will identify key problems that need to
be studied; isolate the risks and benefits associated with behavioral,
clinical, or evaluation research designed to enroll this group as
subjects; and pose solutions that will meet the needs of regulators,
scientists, and the elderly.

The program is designed to be of interest to physicians, nurses,
pharmacists, scientific investigators, other health care professionals,
clergy, lawyers, medical, nursing, social work students, and
psychologists as well as IRB members and administrators.  Attention
will be paid to Federal regulations with special emphasis on the
assessment of risks---medical, legal, and psychosocial.  Opportunities
will be available through workshops, question periods, and informal
discussions for participants to exchange ideas and interests with
faculty and OPRR and FDA representatives.

SOUTHEASTERN WORKSHOP

DATES:  January 14 & 15, 1993

LOCATION:
Sheraton Sand Key Resort
1160 Gulf Boulevard
Clearwater Beach, FL  33515
Telephone:  (813) 595-1611

SPONSORS:
University of South Florida
Florida A&M University

REGISTRATION:
Ms. Eileen Highsmith
Executive Secretary
University of South Florida
4202 E. Fowler Avenue (MP.FAO-126)
Tampa, FL  33620-7900
Telephone:  (813) 974-2897

TITLE:  Barriers to Informed Consent:  Language, Age Factors, Trauma,
and Women/Minority Issues

DESCRIPTION:  Today's researchers face numerous barriers to obtaining
an informed consent.  Such issues as age, language, mental capacity,
and sobriety may affect the ability of subjects to give a truly
informed consent.  Many of these barriers often impact the pool of
subjects that an investigator is willing (or able) to use in a research
project.  In addition, recent legislation from the Congress was
designed to address the issue of inadequate numbers of women and
minorities in research projects.  This conference has been designed to
address three main areas in which barriers to informed consent may
exist:  mental competence, ethnic and gender issues, and research with
children and the elderly.

The conference program is designed to be of value to physicians,
nurses, pharmacists, scientific investigators, and other health care
professionals.  IRB members, students in health care areas, and
administrators will also benefit from the conference.  Attention will
be given to Federal regulations governing research on human subjects,
with special emphasis placed on the assessment of risks---medical,
legal, and psychosocial.  Ample opportunities will be provided to
exchange ideas and interests through question and answer sessions and
informal discussions.

SOUTHWESTERN WORKSHOP

DATES:  February 12 & 13, 1993

LOCATION:
Sheraton Tempe Mission Palms Hotel
60 East 5th Street
Tempe, AZ  85281
Telephone:  (602) 894-1400

SPONSORS:
Arizona State University
Northern Arizona University

REGISTRATION:
Ms. Carol Jablonski
IRB Coordinator
Office of the Assistant Vice President for Research
Arizona State University
Tempe, AZ  85287-3403
Telephone:  (602) 965-6788

TITLE:  Contemporary Issues in Human Subject Research:  Challenges for
Todays IRBs

DESCRIPTION:  This program is designed to be a practical working
session to explore contemporary issues in human subjects protection
including regulations and assurances, categorization of research
protocols, uses of special populations, experimental design and
scientific merit, fetal tissue research, ethical/legal issues in human
subjects research, and conflict of interest.  As appropriate, topics
will be discussed from the perspective of the clinical researcher and
the behavioral/social science researcher.  Issues will be discussed in
a panel format with ample time for audience questions.  An outstanding
faculty has been assembled.

This program should be of interest to researchers in clinical medicine
and the behavioral and social sciences, Institutional Review Board
members, university and hospital administrators, lawyers, ethicists,
health care practitioners, students, and other persons with interests
in human subject protection issues.

INQUIRIES

For further information regarding these workshops or future NIH/FDA
National Human Subject Protections Workshops, please contact:

Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101

$$N2 END ************************************************************

$$N3 BEGIN **********************************************************

PHS GRANTS AND CONTRACTS TRAINING COURSE

NIH GUIDE, Volume 21, Number 31, August 28, 1992

P.T. 34; K.W. 1014002, 1014006

Public Health Service

SUMMARY:  The Office of the Assistant Secretary for Health is
announcing a training course entitled "Orientation to PHS Grants and
Contracts Activities for Applicants and Recipients of Awards" which
will be presented 12 times at locations around the country during FY
1993.  Complete information as to locations and dates is provided below
under SUPPLEMENTARY INFORMATION.

DATES:  To receive consideration for a particular course session,
applications must be received by the close of business on the deadline
date specified under SUPPLEMENTARY INFORMATION below.

SUPPLEMENTARY INFORMATION:

COURSE TITLE:  "Orientation to PHS Grants and Contracts Activities for
Applicants and Recipients of Awards."  NOTE: This is not a course on
grant-writing.  Rather, it is designed to provide a broad overview of
how to conduct business with PHS using the grant and contract
mechanisms.

COURSE DESCRIPTION:  This is a two-day course that is designed to
provide applicants for and recipients of PHS grants and contracts a
better understanding of the procedures and expectations in applying for
funding and administering an award from the PHS.  Day one of the course
concentrates on the grants process; day two is devoted to contracting.
Students will be provided with a broad overview of conducting business
with the PHS including how it is organized, when the grant or contract
mechanism is used, how the PHS contracts and grants processes are
structured, how to identify grant and contract funding opportunities,
how to submit effective applications and proposals, and how to properly
administer a contract or grant after it has been awarded.

TARGET POPULATION:  Grant and contract staff of organizations that are
presently doing business with the PHS or that plan to submit
applications for grants or proposals for contracts.  The course is
intended for staff who are inexperienced with the grant and contract
mechanisms.

DATES - 1992             LOCATIONS                         APPLICATION
DEADLINES

October 13-14            Winston-Salem, NC                 September 10
November 9-10            Atlanta, GA                       October 10
December 7-8             Rockville, MD                     October 10

DATES - 1993

January 25-26            San Diego, CA                     October 10
February 22-23           Kansas City, MO                   January 10
March 17-18              Dallas, TX                        January 10
April 19-20              San Francisco, CA                 January 10
May 17-18                Seattle, WA                       January 10
June 15-16               Rockville, MD                     May 10
July 12-13               Boston, MA                        May 10
August 16-17             Chicago, IL                       May 10
September 20-21          Denver, CO                        May 10

All courses will be held from 8:30 AM to 5:00 PM both days.

Selection will be made on a first-come, first-served basis.

Early application is encouraged because these offerings are filled
rapidly.

COURSE OUTLINE:

DAY 1

Introduction to PHS Assistance (grants/cooperative agreements) and
Acquisition (contracts):  PHS Mission and Organizational Structure;
Assistance vs. Acquisition (The Federal Grant and Cooperative Agreement
Act); PHS Grant and Contract Expenditures and Recipients; Introduction
to Types and Purposes of PHS Grants; Roles of PHS Grants and Program
Management Staff.

Seeking and Applying for PHS Grants/Cooperative Agreements: Sources of
Information; Understanding Program Announcements; The Application
Package; The Complete, Effective Application; Competition and Objective
Review.

Negotiation and Award Process for Grants/Cooperative Agreements:  Cost
Analysis and Preaward Review; Negotiating--Clarifying and Revising
Proposed Activities; Funding Outcomes; Contents of a Grant Award
Document; General and Special Conditions.

Grant/Cooperative Agreement Post-Award Issues and Concerns: Monitoring;
Audit; Appeals; Progress Reports; Drawdowns; Financial Status Reports;
Grant Budget Control; Cost Principles and Unallowable Costs;
Purchasing; Property Management.

DAY 2

Seeking PHS Contracts:  Identifying PHS Contracting Opportunities; The
Legal Framework of PHS Contracting; Small Business Contracting
Programs; Roles of PHS Contracting and Project Staff.

Responding to Contract Solicitations:  Small Purchases - $25,000 or
Less; Purchases Greater Than $25,000; Preparing the Technical Proposal;
Preparing the Business Proposal.

Proposal Submission, Contract Negotiation, and Award:  Proposal
Submission and Evaluation; Negotiation and Award.

Contract Administration:  Initial Contract Administration Steps;
Significant Contract Administration Concerns.

CLASS SIZE:  Limited to 30 participants per session to maximize
interaction and only one individual per institution, per session.

ATTENDANCE:  Those accepted will be expected to attend both full days
of the course.  A Certificate of Attendance will be issued to all
participants who attend for both days.

COST:  There will be no charge for this course.  Travel and
accommodations will be the responsibility of participants.

NOTIFICATION OF APPLICANTS:

Applicants selected will be notified of their acceptance approximately
one month in advance of the course and provided with information on the
exact training location and suggested accommodations.  Persons not
selected will not be notified.

TO APPLY:  Submit to the Training Coordinator a letter on the employing
organization's letterhead which provides all of the following
information.  Incomplete applications cannot be considered:

Name of applicant
Employing organization: name, address, and telephone number
Position title of applicant
Years of experience with PHS grants, contracts, or both
Principal area of interest (grants, contracts, or both)
Reason for wanting to take this course (100 words or less)
Course session desired

INQUIRIES

Letters of application and requests for information are to be sent to:

Training Coordinator
Grants Policy Branch
Division of Grants and Contracts
Office of the Assistant Secretary for Health
Parklawn Building, Room 17A-45
5600 Fishers Lane
Rockville, MD  20857

$$N3 END ************************************************************

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$R1 BEGIN NIH-92-HL-09-P FULL-TEXT *********************************

OBESITY PREVENTION IN AMERICAN INDIANS/ALASKA NATIVES:  COORDINATING
CENTER

NIH GUIDE, Volume 21, Number 31, August 28, 1992

RFA AVAILABLE:  NIH-92-HL-09-P

P.T. 34; FE; K.W. 0715145, 0745027

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  October 15, 1992
Application Receipt Date:  December 18, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The Division of Epidemiology and Clinical Applications (DECA) invites
cooperative agreement applications for a Coordinating Center to
participate [with an estimated five Field Centers, to be selected under
a separate RFA: NIH-92-HL-08-P, and with the assistance of the National
Heart, Lung, and Blood Institute (NHLBI)] in a collaborative study to
assess the effectiveness of school-based intervention to prevent
obesity in young American Indians/Alaska Natives (Native Americans).
The solicitation is for the initial three-year planning and feasibility
study of a planned nine-year effort.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  The RFA,
Obesity Prevention in American Indians/Alaska Natives, is related to
the priority areas of nutrition, physical activity fitness, educational
and community-based programs, heart disease and stroke, and diabetes
and chronic disabling diseases.  Potential applicants may obtain a copy
of "Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic, for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal Government.  Foreign organizations are
not eligible to apply and domestic applications may not include
international components.  Applications from minority individuals,
especially American Indians/Alaska Natives, and women are encouraged.

MECHANISM OF SUPPORT

The administrative and funding mechanism to be used to undertake this
project will be a cooperative agreement (U01), an assistance mechanism.
Under the cooperative agreement, the NIH assists, supports, and/or
stimulates and is involved substantially with recipients in conducting
a study by facilitating performance of the effort in a "partner" role.

FUNDS AVAILABLE

One award for the Coordinating Center will be made under the RFA.  A
maximum of $6.3 million (including direct and indirect costs) over a
three-year period will be awarded for Field Centers and the
Coordinating Center with at least two-thirds for Field Centers.  First
year total funding will be $2.0 million.

RESEARCH OBJECTIVES

Background

The Native American population, including American Indians and Alaska
Natives, totals nearly 1.5 million from over 500 tribes and nearly 300
reservations and Alaska Native villages.  Earlier in this century,
heart disease was rarely noted in Native Americans but, in the last
decade, cardiovascular disease has become the leading cause of death in
Native Americans.  Several factors may be responsible for this
increase, one of which is an increasing incidence of obesity.
Reduction of the prevalence of obesity in Native Americans has been
designated as a goal for improving the health of this minority
population.  The RFA attempts to address these issues with a project on
primary prevention of obesity in young Native Americans.

Objectives and Scope

This study is envisioned as a nine-year effort to develop and test
intervention to reduce the rate of weight gain in schoolchildren of the
Native American community.  The study consists of two phases.
Feasibility of the concept will be determined during the first three
years of the study (the subject of the RFA described by this
announcement).  If feasibility is demonstrated, the NHLBI anticipates
inviting competitive continuations for implementing the full-scale
study over the next six years.  The planning and feasibility study
(Phase I) may be loosely divided into three subphases covering about a
three-year period.

Phase I(a):  Planning and Protocol Development - 1 year.
Phase I(b):  Training and Pilot-testing - 1 year and 6 months.
Phase I(c):  Post-Pilot-testing Assessment - 6 months.

Possible objectives of Phase I(a) are to develop a complete study
protocol, data forms, and a manual of operations, and to recruit and
prepare for the work with the schools.

The main activities of Phase I(b) are envisioned to include training of
intervention personnel, conducting the pilot test of the study protocol
that was developed in Phase I(a), and evaluating and cooperatively
revising the study materials and methods.

Phase I(c) is expected to include refinement of the protocol,
intervention and measurement manuals and study materials as well as
manuscript preparation.  Analyses of the data will be completed.  The
goal of these analyses will be to evaluate acceptance and adherence to
interventions and the effects of the interventions.

The planning and feasibility study is expected to be completed over
approximately a three-year period.  During this period, investigators
from the Field Centers, Coordinating Center, and the NHLBI will
collaboratively develop the study design, materials, forms, protocol,
and manual of operations to be cooperatively followed by all Field
Centers and Coordinating Center in the pilot test and subsequent
full-scale study if it is approved.  Some aspects of the protocol may
vary by center to meet local conditions and needs.  The expertise of
the investigators will be fully utilized to collaboratively determine
the most appropriate approach to prevent obesity among young Native
Americans.

The objective of Phase II - not within the scope of the current awards,
but relevant to the current RFA - will be to conduct a full-scale
randomized intervention trial to prevent the development of obesity.
It is envisioned that the intervention will be focussed on
pre-adolescent elementary schoolchildren and that about 3000 Native
American students study-wide will participate in intervention and
control groups.  Schools are expected to be the unit of randomization.
An estimated six schools per center may be required in the full-scale
study.  The intervention is envisioned to last three to four years,
depending on the time needed to show measurable difference in the
selected obesity index between the intervention and control groups.
(Note that this is not weight loss but a reduction in the rate of
weight gain.)  Data analysis and publication of study results will
follow the completion of the intervention.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by October 15, 1992, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of applications.
It allows the NHLBI staff to estimate the potential review workload and
to avoid conflict of interest in the review.

The letter of intent is to be sent to:

C. James Scheirer, Ph.D.
Review Branch, Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 548
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7363
FAX:  (301) 402-1660

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these awards.  These forms are available at most
institutional business offices; from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, 5333
Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/496-7441;
and from the NIH Project Scientists named below.

Applications must be received by December 18, 1992.  An application not
received by this date will be considered ineligible.

REVIEW CONSIDERATIONS

Applicants are encouraged to submit and describe their own ideas on how
best to meet the goals of the study, but they are expected to address
issues identified under SPECIAL REQUIREMENTS of the Request for
Applications.  NOTE THAT THIS DOCUMENT IS NOT THE REQUEST FOR
APPLICATIONS. Applications will be judged primarily on the scientific
quality of the application, the discussion of considerations relevant
to the RFA, expertise of the investigators, their capability to perform
the work proposed, and a demonstrated willingness to work together with
other Centers and the NHLBI Project Scientists.

The review group will assess (as further detailed in the RFA):

o  Scientific merit of the study.

o  Organizational and administrative ability to serve as a Coordinating
Center for a multicenter randomized controlled intervention trial.

o  Qualifications, experience, and commitment of key personnel.

o  Facilities and equipment to function as a Coordinating Center for a
multicenter intervention trial.

o  Appropriateness of the budget for the work proposed.

AWARD CRITERIA

Applications recommended by the National Heart, Lung, and Blood
Advisory Council will be considered for award based upon (a) scientific
and technical merit and the requirements explicitly stated in the RFA,
(b) program balance, including in this instance, sufficient
compatibility of features to make a successful collaborative program a
reasonable likelihood, and (c) availability of funds.

Time Table

Letter of Intent:                                            October
15, 1992
Application Receipt Date:                                    December
18, 1992
Review by National Heart, Lung, and Blood Advisory Council:  May, 1993
Anticipated Award Date:                                      July 1,
1993

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.
Requests for a copy of the RFA and inquiries regarding this
announcement may be directed to:

Richard R. Fabsitz
Clinical and Genetic Epidemiology Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building, Room 3A17
7750 Wisconsin Avenue
Bethesda, MD  20892
Telephone:  (301) 496-4333

Direct fiscal and administrative matters to:

Marie Willett
Deputy Chief, Grants Operations Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A12
Bethesda, MD  20892
Telephone:  (301) 496-7255

AUTHORITY AND REGULATIONS

This project is described in the Catalog of Federal Domestic Assistance
No. 93.837.  Awards are made under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410, as amended by Public
Law 99-158, 42 USC 241 and 285) and administered under PHS grants
policies and Federal Regulations 42 CFR 52 and 45 CFR 74.  This project
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

$$R1 END ************************************************************

$$R2 BEGIN NIH-92-HL-08-P FULL-TEXT *********************************

OBESITY PREVENTION IN AMERICAN INDIANS/ALASKA NATIVES:  FIELD CENTER

NIH GUIDE, Volume 21, Number 31, August 28, 1992

RFA AVAILABLE:  NIH-92-HL-08-P

P.T. 34, FE; K.W. 0715145, 0745027

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  October 15, 1992
Application Receipt Date:  December 18, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The Division of Epidemiology and Clinical Applications (DECA) invites
cooperative agreement applications for an estimated five Field Centers
to participate [with the Coordinating Center, to be selected under a
separate RFA: NIH-92-HL-09-P, and with the assistance of the National
Heart, Lung, and Blood Institute (NHLBI)] in a collaborative study to
assess the effectiveness of school-based intervention to prevent
obesity in young American Indians/Alaska Natives (Native Americans).
The solicitation is for the initial three-year planning and feasibility
study of a planned nine-year effort.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Obesity Prevention in American Indians/Alaska Natives, is related to
the priority areas of nutrition, physical activity fitness, educational
and community-based programs, heart disease and stroke, and diabetes
and chronic disabling diseases.  Potential applicants may obtain a copy
of "Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic, for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal Government.  Foreign organizations are
not eligible to apply and domestic applications may not include
international components.  Applications from minority individuals,
especially American Indians/Alaska Natives, and women are encouraged.

MECHANISM OF SUPPORT

The administrative and funding mechanism to be used to undertake this
project will be a cooperative agreement, an assistance mechanism.
Under the cooperative agreement, the NIH assists, supports, and/or
stimulates and is involved substantially with recipients in conducting
a study by facilitating performance of the effort in a "partner" role.

FUNDS AVAILABLE

An estimated five awards for Field Centers will be made under the RFA.
A maximum of $6.3 million (including direct and indirect costs) over a
three-year period will be awarded for Field Centers and the
Coordinating Center with at least two-thirds for Field Centers.  First
year total funding will be $2.0 million.

RESEARCH OBJECTIVES

Background

The Native American population, including American Indians and Alaska
Natives, totals nearly 1.5 million from over 500 tribes and nearly 300
reservations and Alaska Native villages.  Earlier in this century,
heart disease was rarely noted in Native Americans, but in the last
decade, cardiovascular disease has become the leading cause of death in
Native Americans.  Several factors may be responsible for this
increase, one of which is an increasing incidence of obesity.
Reduction of the prevalence of obesity in Native Americans has been
designated as a goal for improving the health of this minority
population.  The RFA attempts to address these issues with a project on
primary prevention of obesity in young Native Americans.

Objectives and Scope

This study is envisioned as a nine-year effort to develop and test
interventions to reduce the rate of weight gain in schoolchildren of
the Native American community.  The study consists of two phases.
Feasibility of the concept will be determined during the first three
years of the study (the subject of the RFA described by this
announcement).  If feasibility is demonstrated, the NHLBI anticipates
inviting competitive continuations for implementing the full-scale
study over the next six years.

The planning and feasibility study (Phase I) may be loosely divided
into
three subphases covering about a three-year period.

Phase I(a):  Planning and Protocol Development - 1 year.
Phase I(b):  Training and Pilot-testing - 1 year and 6 months.
Phase I(c):  Post-Pilot-testing Assessment - 6 months.

Possible objectives of Phase I(a) are to develop a complete study
protocol, data forms, and a manual of operations, and to recruit and
prepare for the work with the schools.

The main activities of Phase I(b) are envisioned to include training of
intervention personnel, conducting the pilot test of the study protocol
which was developed in Phase I(a), and evaluating and cooperatively
revising the study materials and methods.

Phase I(c) is expected to include refinement of the protocol,
intervention, and measurement manuals and study materials as well as
manuscript preparation.  Analyses of the data will be completed.  The
goal of these analyses will be to evaluate acceptance and adherence to
interventions and the effects of the interventions.

The planning and feasibility study is expected to be completed over
approximately a three-year period.  During this period, investigators
from the Field Centers, Coordinating Center, and the NHLBI will
collaboratively develop the study design, materials, forms, protocol,
and manual of operations to be cooperatively followed by all Field
Centers and Coordinating Center in the pilot test and subsequent
full-scale study if it is approved.  Some aspects of the protocol may
vary by center to meet local conditions and needs.  The expertise of
the investigators will be fully utilized to collaboratively determine
the most appropriate approach to prevent obesity among young Native
Americans.

The objective of Phase II---not within the scope of the current awards,
but relevant to the current RFA---will be to conduct a full-scale
randomized intervention trial to prevent the development of obesity.
It is envisioned that the intervention will be focussed on
pre-adolescent elementary schoolchildren and that about 3000 Native
American students study-wide will participate in intervention and
control groups.  Schools are expected to be the unit of randomization.
An estimated six schools per center may be required in the full-scale
study.  The intervention is envisioned to last three to four years,
depending on the time needed to show measurable difference in the
selected obesity index between the intervention and control groups.
(Note that this is not weight loss but a reduction in the rate of
weight gain.)  Data analysis and publication of study results will
follow the completion of the intervention.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by October 15, 1992, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of applications.
It allows the  NHLBI staff to estimate the potential review workload
and to avoid conflict of interest in the review.

The letter of intent is to be sent to:

C. James Scheirer, Ph.D.
Review Branch, Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 548
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7363
FAX:  (301) 402-1660

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these awards.  These forms are available at most
institutional business offices; from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, 5333
Westbard Avenue, Room 449, Bethesda, MD 20892, telephone 301/496-7441;
and from the NIH Project Scientists named below.

Application must be received by December 18, 1992.  An application not
received by this date will be considered ineligible.

REVIEW CONSIDERATIONS

Applicants are encouraged to submit and describe their own ideas on how
best to meet the goals of the study, but they are expected to address
issues identified under SPECIAL REQUIREMENTS of the Request for
Applications. NOTE THAT THIS DOCUMENT IS NOT THE REQUEST FOR
APPLICATIONS.  Applications will be judged primarily on the scientific
quality of the application, the availability of a study sample with
adequate numbers of students, evidence of a commitment of the Native
American community to the proposed study and study investigators, the
discussion of considerations relevant to the RFA, expertise of the
investigators, their capability to perform the work proposed, and a
demonstrated willingness to work together with other Centers and the
NHLBI Project Scientists.

The review group will assess (as further detailed in the RFA):

o  Scientific merit of the study.

o  Plans to recruit schools and secure student, family and community
participation.

o  Qualifications, experience, and commitment of key personnel.

o  Facilities, equipment and organizational structure to effectively
implement intervention and data collection procedures.

o  Appropriateness of the budget for the work proposed.

AWARD CRITERIA

Applications recommended by the National Heart, Lung, and Blood
Advisory Council will be considered for award based upon (a) scientific
and technical merit and the requirements explicitly stated in the RFA,
(b) program balance, including in this instance, sufficient
compatibility of features to make a successful collaborative program a
reasonable likelihood, and (c) availability of funds.

Time Table

Letter of Intent:                                            October
15, 1992
Application Receipt Date:                                    December
18, 1992
Review by National Heart, Lung, and Blood Advisory Council:  May, 1993
Anticipated Award Date:                                      July 1,
1993

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.
Requests for a copy of the RFA and inquiries regarding the announcement
may be directed to:

Richard R. Fabsitz
Clinical and Genetic Epidemiology Branch
Division of Epidemiology and Clinical Applications
National Heart, Lung, and Blood Institute
Federal Building, Room 3A17
7750 Wisconsin Avenue
Bethesda, MD  20892
Telephone:  (301) 496-4333

Direct fiscal and administrative matters to:

Marie Willett
Deputy Chief, Grants Operations Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A12
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7255

AUTHORITY AND REGULATIONS

This project is described in the Catalog of Federal Domestic Assistance
No. 93.837.  Awards are made under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410, as amended by Public
Law 99-158, 42 USC 241 and 285) and administered under PHS grants
policies and Federal Regulations 42 CFR 52 and 45 CFR 74.  This project
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

$$R2 END ************************************************************

$$R3 BEGIN DA-93-01 FULL-TEXT ***************************************

DEVELOPMENT OF INNOVATIVE METHODS TO IDENTIFY MEDICATIONS FOR TREATING
COCAINE ABUSE

NIH GUIDE, Volume 21, Number 31, August 28, 1992

RFA AVAILABLE:  DA-93-01

P.T. 34; K.W. 0404009, 0710085, 0710100

National Institute on Drug Abuse

Application Receipt Date:  December 11, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE GRANTS MANAGEMENT BRANCH
IDENTIFIED IN INQUIRIES, BELOW.

PURPOSE

The Medications Development Division of the National Institute on Drug
Abuse (NIDA) invites the submission of research applications to develop
innovative preclinical (nonhuman) methods for the identification of
potential treatment agents for the entire spectrum of cocaine abuse,
from pre-addiction through abstinence, relapse, and recovery.  The
methods may be based on behavioral, neurophysiological, neurochemical,
or other approaches as long as a strong case is made for relevance to
human cocaine abuse and its pharmacologic treatment.  These methods
should be novel or expand other underdeveloped or unrecognized methods
as tools for evaluating pharmacotherapies for drug abuse disorders.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA, "The
Development of Innovative Methods to Identify Medications for Treating
Cocaine Abuse," is related to priority area of health promotion,
alcohol and other drugs. Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0 or
Summary Report:  Stock No. 017-001-00473-1) through the Superintendent
of Documents, Government Printing Office, Washington, DC 20492-9325
(telephone 202-783-3238).

ELIGIBILITY

Applications may be submitted by foreign and domestic, nonprofit and
for-profit, public and private organizations such as universities,
colleges, hospitals, laboratories, research institutions, units of
State and local governments, and eligible agencies of the Federal
Government.  Applications from minority individuals and women are
encouraged.  Foreign applicants are not eligible for First Independent
Research Support and Transition (FIRST) Awards (R29).

MECHANISMS OF SUPPORT

Support mechanisms include the research projects (R01) and the FIRST
Award (R29).  Responsibility for the planning, direction, and execution
of the proposed project will be solely that of the applicant.  For
information on the special requirements of the FIRST Award (R29),
contact the program staff listed at the end of the announcement.  The
total project period for applications submitted in response to the
present RFA may not exceed five years for the R01 and R29.

This RFA is a one-time solicitation.  Future unsolicited competing
continuation applications will compete with all investigator-initiated
applications and be reviewed according to the customary peer review
procedures.  R29 Awards may not be renewed, but awardees may apply for
an R01.

FUNDS AVAILABLE

Applications submitted in response to this announcement will compete
for approximately $1,000,000 total costs that has been made available
for this purpose in Fiscal Year 1993.  It is expected that
approximately four to five grants will be supported.  This level of
support is dependent on the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NIDA, awards pursuant to
this RFA are contingent upon the availability of funds for this
purpose.

RESEARCH OBJECTIVES

The areas of research interest that may be funded include those that
are innovative, that develop new methods of drug discovery for cocaine
abuse pharmacotherapies, and that will advance the development of a new
medication for the treatment of cocaine abuse.  In general, these may
include:

o  an innovative behavioral model of craving that does not employ the
standard self-administration paradigms

o  models of behavioral toxicity that look at attenuation of important
adverse effects of cocaine through a new approach

o  techniques to study post-addictive behavior as experimental models
of recovery and possible relapse

o  neurophysiological techniques that utilize the putative underlying
mechanisms of cocaine abuse to identify new medications

o  electrophysiological methods that will identify and develop new
pharmacotherapeutic agents

These areas of research interest are not intended to be all-inclusive.
However, experimental animal models to develop therapeutic
interventions for cocaine abuse are extremely limited.  Therefore, a
major research effort is required to design innovative approaches to
expand the current methods and models to those that have not been
explored.  Well-known models of drug abuse to study cocaine are of
interest only insofar as the application constitutes an innovative
approach.  It is anticipated that no single method will be definitive
and that both behavioral and non-behavioral techniques will be
identified and developed.

STUDY POPULATIONS

This RFA is targeted for preclinical studies in non-human species,
including rodents, monkeys, cell preparations from non-human sources.
The PHS Policy on Humane Care and Use of Laboratory Animals by Awardee
Institutions requires that applicant organizations establish and
maintain appropriate policies and procedures to ensure the humane care
and use of live vertebrates involved in research, research training,
and biological testing activities supported by PHS.  All institutions
are required to comply, as applicable, with the Animal Welfare Act as
amended (7 USC 2131 et sec.).  These documents are available from the
Office for Protection from Research Risks (OPRR), National Institutes
of Health, Building 31, Room 5B59, Bethesda, MD 20892.

An applicant organization proposing to use vertebrate animals in
PHS-funded studies must file an Animal Welfare Assurance Form with
OPRR.  As part of the Assurance, which commits the applicant
organization to comply with PHS policy, the applicant organization must
appoint an Institutional Animal Care and Use Committee (IACUC), which
is required to review and approve those sections of application for PHS
support that involve vertebrate animals.  IACUC approval should be
submitted at the time of application for studies which involve animal
subjects.

If animal subjects will be involved at sites other than the applicant
organization, the applicant must identify, within the application, the
assurance status of each participant and must arrange the appropriate
certifications and verifications.

APPLICATION PROCEDURES

Applicants must request the RFA, which contains additional information
for applying under this RFA.  Applications are to be submitted using
the grant application form PHS 398 (rev. 9/91).  Application kits
containing the necessary forms and instructions for research grants may
be obtained from business offices or offices of sponsored research at
most universities, colleges, medical schools, and other major research
facilities.  If such a source is not available, the materials may be
requested from the Office of Grants Inquiries, Division of Research
Grants, National Institutes of Health, Room 449, Westwood Building,
5333 Westbard Avenue, Bethesda, MD 20892, telephone (301) 496-7441.

Applications must be received by December 11, 1992.  Applications
received after each this date will be returned to the applicants
without review.

REVIEW CONSIDERATIONS

Criteria for scientific/technical merit review of the applications will
include the following:

o  Relevance of objectives to the goal of this program, as stated in
the RFA including:
(a) Is the method innovative?
(b) Is the method workable as either a screening technique or as an
evaluation technique?
(c) Will the method identify potential treatment agents?

o  Adequacy of the research design and methodology

o  Applicability of the project to clinical situations covering
specific aspects of the addictive process from pre-addiction through
craving, abstinence, relapse, and recovery

o  Potential contribution to the development of medications to treat
cocaine abuse

o  Demonstrated scientific expertise of the Principal Investigator and
other key personnel

o  Availability of adequate facilities, other resources, and
collaborative arrangements necessary for the research

o  Appropriateness of budget estimates for the proposed research
activities

AWARD CRITERIA

In making funding decisions, the Alcohol, Drug Abuse, and Mental Health
Administration (ADAMHA) and the NIDA will give consideration to
availability of funds, potential contribution to the medications
development program, overall scientific and technical merit as
determined by peer review, needs and balances of the medications
development portfolio, relevance to program goals and objectives, as
stated in this RFA under RESEARCH OBJECTIVES.

INQUIRIES

Requests for the RFA and inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is
encouraged.

Direct inquiries regarding programmatic issues to:

Heinz Sorer, Ph.D.
Medications Development Division
National Institute on Drug Abuse
5600 Fishers Lane, Room 11A-55
Rockville, MD  20857
Telephone:  (301) 443-6270

Direct inquiries regarding fiscal matters to:

Shirley A. Denney
Chief, Grants Management Branch
National Institute on Drug Abuse
5600 Fishers Lane, Room 8A-55
Rockville, MD  20857
Telephone:  (301) 443-6710

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance, Number 93.279.  Awards are made under authorization of the
Public Health Service Act, section 301 and 515 (42 USC 241 and 290cc)
and administered under PHS grants policies and Federal Regulations 42
CFR 92 and 45 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

$$R3 END ************************************************************

$$R4 BEGIN DK-93-03 FULL-TEXT ***************************************

CAREER DEVELOPMENT AWARDS FOR UNDERREPRESENTED MINORITY
CLINICIAN-INVESTIGATORS

NIH GUIDE, Volume 21, Number 31, August 28, 1992

RFA AVAILABLE:  DK-93-03

P.T. 34, FF; K.W. 0785035, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date:  November 4, 1992
Application Receipt Date:  December 3, 1992

PURPOSE

The purpose of this solicitation is to increase the number of
underrepresented minority clinicians who can conduct high-quality
independent research and provide leadership in the areas of diabetes,
endocrinology, metabolism and metabolic diseases, including cystic
fibrosis; nutrition, eating disorders, obesity, organ systems and
components associated with the gastrointestinal tract; renal and
urological diseases, and hematology.

This Request for Applications (RFA) is limited to the Clinical
Investigator Award (CIA/K08) and the Physician Scientist Award
(PSA/K11).  Each of these mechanisms is tailored to a particular stage
of the investigator's career.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Career Development Awards for Underrepresented Minority Clinician-
Investigators, is related to the priority area of nutrition and
diabetes and chronic disabling disorders.  Potential applicants may
obtain a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal Government.

Applicants for the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) CIA and the NIDDK PSA must:

o  Hold an M.D., D.O., or other appropriate clinical degree;

o  Not have been a Principal Investigator on a PHS-supported research
project; and

o  Commit at least 75 percent time to CIA activities.

In addition, applicants for the PSA must have completed at least one
postgraduate year of clinical training by the time the award is made.
Applicants for the CIA must have had approximately four to eight years
of postdoctoral experience, both clinical and research (a minimum of
two years of each) by the projected start of the award.

Potential candidates must be citizens or non-citizen nationals of the
United States or its possessions and territories or must have been
lawfully admitted to the United States for permanent residence at the
time of the application and must be a member of a minority group that
is underrepresented in biomedical or behavioral science.

Applicants applying for the CIA or the PSA under this solicitation must
have completed, by the time an award would be activated, a residency in
internal medicine, surgery, or pediatrics.

MECHANISMS OF SUPPORT

The mechanisms of support to be used are the Clinical Investigator
Award (K08) and the Physician Scientist Award (K11).  Detailed
guidelines can be obtained from the office of sponsored programs at
most research institutions or from the Office of Grants Inquiries,
Division of Research Grants, NIH, telephone (301) 496-7441.  Awards
will be administered under PHS grants policy as stated in the PHS
Grants Policy Statement.

FUNDS AVAILABLE

For FY 1993, the NIDDK plans to make up to a total of eight awards for
applications submitted in response to this RFA.  However, this funding
level is dependent upon the receipt of a sufficient number of highly
meritorious applications.  Although this program is provided for in the
financial plans of the NIDDK, the award of grants pursuant to this RFA
is also contingent upon the availability of funds for this purpose.

RESEARCH OBJECTIVES

The objective of this solicitation is to increase the number of
underrepresented clinicians who can conduct high-quality research and
provide leadership in the areas of diabetes, endocrinology, metabolism
and metabolic diseases, including cystic fibrosis; nutrition, eating
disorders, obesity, organ systems and components associated with the
gastrointestinal tract; renal and urological diseases, and hematology.

NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
STUDY POPULATIONS

It is NIH and ADAMHA policy that clinical research studies include
women and minorities in study populations so that research findings can
be of benefit to all persons at risk of the disease, disorder, or
condition under study.  This policy is intended to apply to females and
males of all ages. If women or minorities are excluded or inadequately
represented in a clinical research project, particularly in proposed
population based studies, a clear compelling rationale must be
provided.

LETTER OF INTENT

Prospective applicants are asked to submit, by November 4, 1992, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the applicant, the
name of the sponsor, the names of all participating institutions, and
the number and title of this RFA.  However, a letter of intent is not
required.

The letter of intent is to be sent to:

Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892
Telephone:  (301) 496-7083

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91), is to be used
in applying for the K awards.  Special instructions for preparing CIA
and PSA applications can be found in the booklet "The K Awards,"
October 1991.  These forms and "The K Awards" booklet are available
from most institutional business offices and from the Office of Grants
Inquiries, Division of Research Grants (address below) or call (301)
496-7441.

Applicants must submit a signed, typewritten original of the
application, including the Checklist, and three signed exact
photocopies, in one package to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At time of submission, two additional copies of the application must be
sent under separate cover to:

Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892

Applications must be received by December 3, 1992.

REVIEW CONSIDERATIONS

Applications will be reviewed initially by the Division of Research
Grants (DRG) for completeness.  Incomplete applications will be
returned to the applicant without further consideration.  Those
applications that are complete and responsive will be evaluated for
scientific/technical merit by an appropriate peer review group convened
by the NIDDK.

The review criteria for applications received in response to this RFA
are the same as those for unsolicited K08 and K11 applications.

INQUIRIES

Written and telephone inquiries about this RFA and the opportunity to
clarify any issues or questions from potential applicants are
encouraged.

Direct requests and inquiries regarding programmatic issues to:

Lois F. Lipsett, Ph.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
Telephone:  (301) 496-7433

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
Nos. 93.847, 93.848, and 93.849. Awards are made under authorization of
the Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 66 and
45 CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.

$$R4 END ************************************************************
Newsgroups: bionet.sci-resources